These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22257102)

  • 1. Chairman's foreword. Recent advances in prostate cancer management.
    Fitzpatrick JM
    BJU Int; 2012 Mar; 109 Suppl 2():v. PubMed ID: 22257102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
    Bahl A; Bellmunt J; Oudard S
    BJU Int; 2012 Mar; 109 Suppl 2():14-9. PubMed ID: 22257100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximizing outcomes in genitourinary cancers across the treatment continuum.
    Fitzpatrick JM; Bellmunt J; Dreicer R; Fleshner NE; Logothetis CJ; Moul JW; Tombal B; Zlotta A
    BJU Int; 2011 Apr; 107 Suppl 2():1-12. PubMed ID: 21382149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.
    Marberger M; Barentsz J; Emberton M; Hugosson J; Loeb S; Klotz L; Koch M; Shariat SF; Vickers A
    BJU Int; 2012 Mar; 109 Suppl 2():1-7. PubMed ID: 22257098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Standards, options and recommendations for the management of prostate cancer: therapeutic decision criteria].
    Chatelard PP;
    Bull Cancer; 2002 Jun; 89(6):619-34. PubMed ID: 12135863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate cancer: news in 2008].
    Salomon L; Descazeaud A
    Prog Urol; 2008 Sep; 18 Suppl 6():S116-24. PubMed ID: 18822261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adapting treatment for prostate cancer according to risk of disease progression.
    Anderson J; Sternberg CN
    Crit Rev Oncol Hematol; 2008 Oct; 68 Suppl 1():S23-31. PubMed ID: 18752970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
    Small EJ; Halabi S; Kantoff P; D'Amico A; Stadler W; Kelley WK; Mohler J; Bajorin D; Vogelzang NJ
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3596s-600s. PubMed ID: 16740791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the medical management of prostate cancer.
    Kirby RS
    Br J Clin Pract; 1996 Mar; 50(2):88-93. PubMed ID: 8731645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced prostate cancer: treatment and patient-centred care.
    Peate I
    Br J Nurs; 2012 Feb 23-Mar 7; 21(4):S24-30. PubMed ID: 22470904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current controversies in the treatment of high-risk prostate cancer.
    Mitchell RE; Chang SS
    Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Update about advanced prostate cancer: diagnosis, treatment and ongoing perspectives].
    Drouin SJ; Rouprêt M
    Prog Urol; 2010 Jun; 20 Suppl 3():S198-202. PubMed ID: 20620965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prostate Cancer Foundation 16th Annual Scientific Retreat: meeting report.
    Rhodes KE; Simons JW; Soule HR
    Prostate; 2010 Jun; 70(8):916-20. PubMed ID: 20166134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group--a new co-operative cancer trials group in genitourinary oncology.
    Sengupta S; Grimison P; Hayne D; Williams S; Chambers S; DeSouza P; Stockler M; McJannett M; Toner G; Davis ID
    BJU Int; 2015 Jun; 115(6):856-8. PubMed ID: 25195815
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary care and management selection in prostate cancer.
    Aizer AA; Paly JJ; Efstathiou JA
    Semin Radiat Oncol; 2013 Jul; 23(3):157-64. PubMed ID: 23763881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future opportunities for the diagnosis and treatment of prostate cancer.
    Watson RW; Schalken JA
    Prostate Cancer Prostatic Dis; 2004 Sep; 7 Suppl 1():S8-S13. PubMed ID: 15365576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prostate cancer unit: a multidisciplinary approach for which the time has arrived.
    Gomella LG
    Eur Urol; 2011 Dec; 60(6):1197-9. PubMed ID: 21871712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.